Dr. Reddy’s Laboratories Files Annual Report with SEC

An update from Dr Reddy’s Laboratories ( (RDY) ) is now available.

On June 7, 2025, Dr. Reddy’s Laboratories announced the filing of its Annual Report in Form 20-F with the United States Securities and Exchange Commission. The report, which includes consolidated financial statements prepared under International Financial Reporting Standards for the fiscal year ending March 31, 2025, is now available on the company’s website. This filing is a regulatory requirement and provides transparency to stakeholders, reinforcing the company’s commitment to compliance and financial disclosure.

The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the production of generic medications, active pharmaceutical ingredients, and proprietary products, focusing on delivering affordable and innovative medicines to patients worldwide.

Average Trading Volume: 2,097,833

Technical Sentiment Signal: Strong Buy

Current Market Cap: $12.84B

For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.